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Abstract
Our objective was to evaluate the concentrations of serum 25-hydroxyvitamin D [25(OH)D], serum calcium, serum phosphorus,
alkaline phosphatase, and parathormone (PTH) in patients with polyarticular juvenile idiopathic arthritis (JIA) and to associate
them with disease duration and activity, bone mineral density and use of medications. In a cross-sectional and controlled study,
30 patients with polyarticular JIA were evaluated and compared to 30 healthy individuals matched for age and gender. Clinical
status, anthropometry, laboratory markers in both patients and controls, and bone mineral density, only in the patients, were
measured. Of the 30 patients included in the study, 23 (76.7%) were female and 16 (53.3%) non-Caucasian; mean age was 14
years (range = 4 to 20 years). Mean disease duration was 5 years (range = 1 to 12 years). The mean concentrations of serum
albumin-corrected calcium (9.04 ± 0.41 mg/dL) and alkaline phosphatase (153.3 ± 100.1 IU) were significantly lower in
patients with JIA than in controls (P , 0.0001 and P = 0.001, respectively). No differences in 25(OH)D, PTH or serum
phosphorus were observed between JIA and control subjects. Regarding 25(OH)D concentration, 8 patients (26.7%) and 5
controls (16.7%) had 25(OH)D concentrations compatible with deficiency (lower than 20 ng/mL) and 14 patients (46.7%) and
18 controls (60%) had concentrations compatible with insufficiency (20-32 ng/mL). These values were not associated with
disease activity, use of medications or bone mineral density. We observed a high frequency of 25(OH)D insufficiency and
deficiency in the study sample. The compromised bone metabolism emphasizes the importance of follow-up of JIA patients.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease of childhood in developed
countries and an important cause of short- and long-term
disability.
The effects of vitamin D have been studied in
experimental models of autoimmunity. In humans, there
are some difficulties in establishing a direct relationship
between vitamin D deficiency and an increase in the
frequency of rheumatic diseases, considering the limita-
tions of available studies, such as different cut-offs used
and small subject samples (1).
Although intake is not the best method for the
assessment of the nutritional status of vitamin D, a higher
intake of this vitamin was found to be inversely related to
the development of rheumatoid arthritis in a cohort study
of 29,368 women (2). In patients with rheumatoid arthritis,
available results suggest a high frequency of vitamin D
insufficiency or deficiency (3-9) and show that vitamin D
supplementation in subjects with active disease may
relieve the symptoms and reduce inflammation (10).
Studies performed in healthy children and adolescents
have shown lower serum concentrations of 25-hydroxy-
vitamin D [25(OH)D] at frequencies ranging from 9 to 62%
(11-13). However, only a few studies have assessed
the serum concentrations of 25(OH)D in children and
adolescents with JIA (14-17).
The aim of the present study was to determine the
serum concentrations of 25(OH)D, serum calcium, serum
phosphorus, alkaline phosphatase, and parathormone
(PTH) in patients with polyarticular JIA and to associate
them or not with disease activity and duration, bone
mineral density and use of medications (glucocorticoids
and hydroxychloroquine) and supplements containing
vitamin D and calcium.
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Patients and Methods
In a cross-sectional and controlled study, 30 patients
of a total of 50 patients with polyarticular JIA were
evaluated according to the criteria of the International
League of Associations for Rheumatology (ILAR) (18).
The patients were followed at the Pediatric Rheumatology
Clinic from September to November 2008. Twenty
patients were excluded due either to other chronic
diseases interfering with the calcium metabolism, or
because they could not perform bone density measure-
ments due to their stature or they did not consent to
participate in the study.
Thirty healthy individuals, matched for gender and age
to the patients, not using supplements containing vitamin
D or calcium were included as controls.
The demographic, clinical and treatment data obtained
with a standardized questionnaire were collected from
the patients’ charts. To assess if the disease was active,
we used the remission criteria described in previous
papers (19,20).
The anthropometric assessment included weight and
height measurements using as reference those proposed
by the World Health Organization (WHO) (21-23).
Pubertal development was determined as recommended
by Marshall and Tanner (24).
Blood samples were collected from patients and
controls after a 12-h fast for the following laboratory
tests: serum phosphorus and serum albumin-corrected
calcium by a colorimetric method with reactant molibidate
and arsenazo, respectively, and alkaline phosphatase
measured by an enzyme activity method with reactant p-
nitrophenyl phosphate (Biochemical Analyzer Olympus
AU640, USA). Urinary calcium and creatinine were
determined in the patients by a colorimetric method using
a specified apparatus. All biochemical analyses of
patients and controls were performed from September
to November 2008, corresponding to the Brazilian spring
months. Since there is seasonal variability in 25(OH)D, we
opted, as done in other studies, to collect the samples in
the spring.
Serum 25(OH)D was determined in 2009 by electro-
chemiluminescence immunoassay using the commercial
kit Elecsys 25(OH)D3 (USA) and serum intact PTH was
determined by immunofluorimetry using the same kit.
Reference 25(OH)D values below 20 ng/mL indicate
deficiency, values between 20 and 32 ng/mL indicate
insufficiency, and values above 32 ng/mL are considered
to be ideal (25). The normal range for PTH is 15 to
65 pg/mL.
The bone mineral density of the spine (L1-L4) was
measured by dual-energy X-ray absorptiometry (DXA)
using a LunarTM DPX-MD plus densitometer (GE-Lunar
Radiation Corporation, USA) equipped with pediatric
software (version 8.5). Bone mineral density was adjusted
for height by the method of Khan et al. (26).
All statistical calculations were done using the
statistical software SPSS 18.0. The chi-square test or,
when indicated, the Fisher test was applied to evaluate
the association between dichotomous variables. The
normality of continuous variables was established by the
Kolmogorov-Smirnov test and is reported as means± SD.
The Student t-test was used to compare groups regarding
the variables under study. Pearson’s correlation coefficient
was used for the quantitative variables with normal
distribution. An a ,5% was adopted (P , 0.05).
An informed consent form was signed by all patients
and controls and/or their legal guardians. The Ethics
Committee of the Universidade Federal de Sa˜o Paulo,
Hospital Sa˜o Paulo (CEP No. 0178/09) approved the
study protocol.
Results
Table 1 shows the characteristics of the study group.
In the JIA group, the mean age at diagnosis was 9 years
(3 to 16 years) and the mean disease duration was 5
years (1 to 12 years); 12/30 (40%) patients had active
disease at the time of evaluation. Six (20%) patients had
positive rheumatoid factor.
No differences in serum 25(OH)D, PTH or phosphorus
concentrations were observed between the JIA and
control groups (Table 2). The mean concentrations of
serum albumin-corrected calcium and alkaline phospha-
Table 1. Demographic characteristics, nutritional status, and
pubertal stage of patients with juvenile idiopathic arthritis.
Variables JIA Controls
Females 23 (76.7) 23 (76.7)
Age at evaluation (range) 14 (4-20) 14 (4-19)
Ethnic origin
Caucasian 14 (46.7) 19 (63.3)
Non-Caucasian 16 (53.3) 11 (36.7)
BMI Z score
Eutrophic 20 (66.7) 30 (100)
Non-eutrophic 10 (33.3) 0
Malnutrition 5 (16.6) 0
Overweight 3 (10.0) 0
Obesity 2 (6.7)* 0
S/A Z score
Low height 5 (17.9) 0
Adequate height 23 (82.1) 28 (100)a
Pubertal stage
Prepubertal stage 6 (20.0) 6 (20.0)
Pubertal stage 24 (80.0) 24 (80.0)
Data are reported as number with percent in parentheses for 30
patients in each group. JIA = juvenile idiopathic arthritis; BMI =
body mass index; S/A = stature for age. *P , 0.05 compared
to controls (chi-square test). aTwo patients were older than
19 years.
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tase were significantly lower in the JIA patients than in the
controls (Table 2). All but 2 patients had calciuria/
creatinuria ratios within the normal range.
Regarding serum 25(OH)D concentrations, 8 patients
(26.7%) and 5 controls (16.7%) had values compatible
with deficiency (,20 ng/mL) and 14 patients (46.7%) and
18 controls (60%) had values compatible with insuffi-
ciency (20-32 ng/mL). Three patients with deficiency and
6 with insufficiency of 25(OH)D had active disease at the
time of evaluation.
Only 1 patient (3.3%) and 1 control (3.3%) had
elevated PTH levels (.65 pg/mL), with 25(OH)D con-
centrations of 24.4 and 39.9 ng/mL, respectively.
25(OH)D concentrations were not different in relation
to ethnicity (P = 0.896), Z body mass index (P = 0.111),
Z stature/age (P = 0.136), or pubertal stage (P = 0.398).
In the JIA group, 3/30 (10%) patients were taking
chloroquine, 11/30 (36.7%) were taking a calcium
supplement and 6/30 (20%) were taking vitamin D. No
patients were on glucocorticoids and/or biphosphonate at
the time of evaluation.
There was no association between 25(OH)D concen-
trations and disease activity (P = 0.737), use of vitamin D
supplements (P = 0.124), use of chloroquine (P = 0.661)
or bone mineral density (P = 0.350) in the JIA patients
(Student t-test).
Three patients had low bone mass density for age; of
those, 1 had insufficient 25(OH)D concentration and 1 had
deficiency. Nine patients had osteopenia; of those, 5 had
25(OH)D insufficiency and 2 had deficiency. One patient
did not perform the DXA. We did not find any correlations
between low bone mass and disease duration or
corticotherapy.
Neither the laboratory tests nor the disease duration
correlated with serum 25(OH)D concentrations: PTH (r =
-0.020, P = 0.877); serum albumin-corrected calcium
(r = 0.057, P = 0.765); serum phosphorus (r = -0.030, P
= 0.818); alkaline phosphatase (r = 0.109, P = 0.408);
calciuria/creatinuria ratio (r = -0.155, P = 0.414);
disease duration (r = 0.079, P = 0.680).
Discussion
In this study involving patients with JIA, we found a
high frequency of 25(OH)D insufficiency and deficiency;
however, these findings did not differ significantly
between patients and controls. Hillman et al. (14), also
assessing serum concentrations of 25(OH)D, did not
report any difference between JIA patients and controls.
Potential explanations for the high frequency of defi-
ciency/insufficiency in both groups may be the frequent
use of sunblocks (27), dietary and life style changes with
consequent adiposity and overweight (28) and season
when the analyses were performed (29,30).
It is important to emphasize that vitamin D deficiency
is a current public health issue that has been increasing,
including in healthy individuals of all ages in developed
and developing countries (11-13). These findings recently
motivated a revision of the recommendations for vitamin
D (31).
There is no consensus regarding the ideal serum
concentrations of 25(OH)D, especially in the pediatric
group, which makes it difficult to compare the results from
different studies. In the present study, we decided to use
the cut-offs suggested by Grant and Holick (25) as
recommended in the revision by the Institute of
Medicine (31).
Another important aspect is the kind of assay used for
25(OH)D analysis, which may lead to a false diagnosis of
vitamin D deficiency. The electrochemiluminescence
immunoassay with the Elecsys Roche’s kit for polyclonal
immunoassay, used in the present study, showed in
previous studies a good correlation with the method
considered as gold standard, i.e., liquid chromatography
mass spectrometry (32,33).
An inverse association between PTH and 25(OH)D
concentrations has been demonstrated in adults and the
persistent increase in PTH levels may result in hyperpar-
athyroidism secondary to the vitamin deficiency
(11,12,29). In children, however, this association has not
been frequently observed, a fact that limits the use of PTH
as a functional marker for vitamin D deficiency (34). We
found only one patient (3.3%) with elevated PTH in spite
of the high frequency of vitamin D insufficiency/deficiency.
Our study showed lower levels of serum albumin-
corrected calcium and alkaline phosphatase in patients
with JIA compared to controls. Those alterations do not
seem to be of clinical significance. A previous study
showed significantly lower osteocalcin and alkaline
phosphatase concentrations in individuals with JIA com-
pared to controls, suggesting reduced bone formation
(14). Lower calcium concentrations in the JIA group, with
no difference in 25(OH)D concentrations may be
explained by the reduced capacity for mineral absorption
described in children with arthritis (17). A study in animal
Table 2. Serum concentrations of 25(OH)D, PTH, calcium,
phosphorus, and alkaline phosphatase of patients with juvenile
idiopathic arthritis.
JIA Controls
25(OH)D (ng/mL) 25.70 ± 8.65 26.92 ± 7.62
PTH (pg/mL) 31.21 ± 12.35 30.04 ± 15.63
Albumin-corrected
calcium (mg/dL)
9.04 ± 0.41* 9.48 ± 0.48
Serum phosphorus (mg/dL) 4.45 ± 0.61 4.17 ± 0.86
Alkaline phosphatase (IU) 153.3 ± 100.1* 285.2 ± 169.9
Data are reported as means ± SD for 30 patients in each group.
JIA = juvenile idiopathic arthritis; 25(OH)D = 25-hydroxyvitamin
D; PTH = parathormone. *P , 0.05 compared to control group
(Student t-test).
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models with induced arthritis revealed a reduction in
1,25(OH)2D receptors, with a consequent reduction in
calcium absorption (35).
We did not find an association between 25(OH)D
concentrations with either disease activity or duration. In
adults with rheumatoid arthritis there are multiple risk
factors for vitamin D deficiency and there is evidence that
the deficiency is associated with the activity (4,7) and
severity of the disease (5,7-9).
Pelajo et al. (36) found a similar frequency of reduced
vitamin D in their study with 154 JIA patients, which was
also not related to disease activity. They observed an
association between 25(OH)D concentrations and age,
ethnicity, body mass index, and season of the year, but
not with vitamin D intake.
A recent publication evaluating the vitamin D binding
protein isoforms showed that some subgroups are related
to the extension of arthritis (37).
The use of supplements containing vitamin D was not
associated with serum 25(OH)D concentrations, with low
values even in patients receiving supplementation. There
is still no consensus on the ideal supplement dose of
vitamin D for patients with JIA. Hillman et al. (17)
observed an increase in serum calcium and 25(OH)D
concentrations, with no impact on bone mineral gain, with
the administration of 2000 IU vitamin D3/day in children
with arthritis. In our clinic, vitamin D supplementation at a
dose of 200 to 800 IU is recommended in association with
500 to 1000 mg calcium for patients with a risk of bone
mass loss (active inflammatory disease and chronic use
of glucocorticoids).
Regarding the medications used for JIA treatment,
only 3 patients were on hydroxychloroquine at the time of
inclusion, with no interference with vitamin D concentra-
tions. In the literature, the effect of hydroxychloroquine on
vitamin D metabolism is still controversial (38).
DXA showed that three (10%) of the 30 patients had
low bone mass density for age. A cross-sectional study in
the literature evaluating bone mass in children and young
adults with JIA showed lower bone mass in the patients
compared to healthy individuals (39). A recently published
prospective study involving patients with JIA showed
reduced bone mass density at the initial evaluation
compared to controls (40).
There are some limitations to the present study,
namely the small sample size, the cross-sectional model
used that does not allow causality evaluations, and no
DXA in the control group. Furthermore, the method
applied for the determination of 25(OH)D concentrations
may be questioned, as well as our cut-off values.
We observed serum insufficient/deficient 25(OH)D
concentrations in a large number of patients, although
with no relation to disease activity or duration, use of
medications and vitamin D supplementation or bone
mineral density. These findings, associated with the
impairment of bone metabolism observed in our patients
even in the absence of alterations in bone mineral density,
emphasize the importance of the follow-up of JIA patients.
Acknowledgments
Research supported by FAPESP (#08/57420-3).
References
1. Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and
autoimmune rheumatologic disorders. Autoimmun Rev
2010; 9: 507-510, doi: 10.1016/j.autrev.2010.02.011.
2. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA,
Saag KG. Vitamin D intake is inversely associated with
rheumatoid arthritis: results from the Iowa Women’s Health
Study. Arthritis Rheum 2004; 50: 72-77, doi: 10.1002/art.
11434.
3. Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW,
Reimold A, et al. Prevalence of vitamin D insufficiency/
deficiency in rheumatoid arthritis and associations with
disease severity and activity. J Rheumatol 2011; 38: 53-59,
doi: 10.3899/jrheum.100516.
4. Vieira VM, Hart JE, Webster TF, Weinberg J, Puett R,
Laden F, et al. Association between residences in U.S.
northern latitudes and rheumatoid arthritis: A spatial
analysis of the Nurses’ Health Study. Environ Health
Perspect 2010; 118: 957-961, doi: 10.1289/ehp.0901861.
5. Braun-Moscovici Y, Toledano K, Markovits D, Rozin A,
Nahir AM, Balbir-Gurman A. Vitamin D level: is it related to
disease activity in inflammatory joint disease? Rheumatol
Int 2011; 31: 493-499, doi: 10.1007/s00296-009-1251-6.
6. Haque UJ, Bartlett SJ. Relationships among vitamin D,
disease activity, pain and disability in rheumatoid arthritis.
Clin Exp Rheumatol 2010; 28: 745-747.
7. Craig SM, Yu F, Curtis JR, Alarcon GS, Conn DL, Jonas B,
et al. Vitamin D status and its associations with disease
activity and severity in African Americans with recent-onset
rheumatoid arthritis. J Rheumatol 2010; 37: 275-281, doi:
10.3899/jrheum.090705.
8. Rossini M, Maddali Bongi S, La Montagna G, Minisola G,
Malavolta N, Bernini L, et al. Vitamin D deficiency in
rheumatoid arthritis: prevalence, determinants and associa-
tions with disease activity and disability. Arthritis Res Ther
2010; 12: R216, doi: 10.1186/ar3195.
9. Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME,
et al. Circannual vitamin d serum levels and disease activity
in rheumatoid arthritis: Northern versus Southern Europe.
Clin Exp Rheumatol 2006; 24: 702-704.
10. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A,
Mitrovic D, et al. Disease modifying and immunomodulatory
effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis
patients. Clin Exp Rheumatol 1999; 17: 453-456.
11. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML.
Prevalence and associations of 25-hydroxyvitamin D defi-
ciency in US children: NHANES 2001-2004. Pediatrics
Serum 25-hydroxyvitamin D in juvenile idiopathic arthritis 101
www.bjournal.com.br Braz J Med Biol Res 46(1) 2013
2009; 124: e362-e370, doi: 10.1542/peds.2009-0051.
12. Gordon CM, Feldman HA, Sinclair L, Williams AL, Kleinman
PK, Perez-Rossello J, et al. Prevalence of vitamin D
deficiency among healthy infants and toddlers. Arch
Pediatr Adolesc Med 2008; 162: 505-512, doi: 10.1001/
archpedi.162.6.505.
13. Peters BS, dos Santos LC, Fisberg M, Wood RJ, Martini LA.
Prevalence of vitamin D insufficiency in Brazilian adoles-
cents. Ann Nutr Metab 2009; 54: 15-21, doi: 10.1159/
000199454.
14. Hillman L, Cassidy JT, Johnson L, Lee D, Allen SH. Vitamin
D metabolism and bone mineralization in children with
juvenile rheumatoid arthritis. J Pediatr 1994; 124: 910-916,
doi: 10.1016/S0022-3476(05)83179-8.
15. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone
mineralization and bone mineral metabolism in children with
juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39: 746-
757, doi: 10.1002/art.1780390506.
16. Falcini F, Ermini M, Bagnoli F. Bone turnover is reduced in
children with juvenile rheumatoid arthritis. J Endocrinol
Invest 1998; 21: 31-36.
17. Hillman LS, Cassidy JT, Chanetsa F, Hewett JE, Higgins
BJ, Robertson JD. Percent true calcium absorption, mineral
metabolism, and bone mass in children with arthritis: effect
of supplementation with vitamin D3 and calcium. Arthritis
Rheum 2008; 58: 3255-3263, doi: 10.1002/art.23809.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN,
Goldenberg J, et al. International League of Associations for
Rheumatology classification of juvenile idiopathic arthritis:
second revision, Edmonton, 2001. J Rheumatol 2004; 31:
390-392.
19. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for
clinical remission for select categories of juvenile idiopathic
arthritis. J Rheumatol 2004; 31: 2290-2294.
20. Machado C, Ruperto N. Consensus in pediatric rheumatol-
ogy part I - criteria definition of inactive disease and
remission in juvenile idiopathic arthritis/juvenile rheumatoid
arthritis. Rev Bras Reumatol 2012; 45: 9-13.
21. Physical status: the use and interpretation of anthropome-
try. Report of a WHO Expert Committee. World Health
Organization Tech Rep Ser 1995; 854: 1-452.
22. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C,
Siekmann J. Development of a WHO growth reference for
school-aged children and adolescents. Bull World Health
Organ 2007; 85: 660-667, doi: 10.2471/BLT.07.043497.
23. Obesity: preventing and managing the global epidemic.
Report of a WHO consultation. World Health Organization
Tech Rep Ser 2000; 894: i-xii-1-253.
24. Marshall WA, Tanner JM. Variations in pattern of pubertal
changes in girls. Arch Dis Child 1969; 44: 291-303, doi:
10.1136/adc.44.235.291.
25. Grant WB, Holick MF. Benefits and requirements of vitamin
D for optimal health: a review. Altern Med Rev 2005; 10: 94-
111.
26. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG,
Kendler DL, et al. Standards and guidelines for performing
central dual-energy X-ray absorptiometry in premenopausal
women, men, and children. J Clin Densitom 2004; 7: 51-64,
doi: 10.1385/JCD:7:1:51.
27. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano
MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US
population: 1988-1994 compared with 2000-2004. Am J Clin
Nutr 2008; 88: 1519-1527, doi: 10.3945/ajcn.2008.26182.
28. Arnberg K, Ostergard M, Madsen AL, Krarup H, Michaelsen
KF, Molgaard C. Associations between vitamin D status in
infants and blood lipids, body mass index and waist
circumference. Acta Paediatr 2011; 100: 1244-1248, doi:
10.1111/j.1651-2227.2011.02273.x.
29. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans
SJ. Prevalence of vitamin D deficiency among healthy
adolescents. Arch Pediatr Adolesc Med 2004; 158: 531-
537, doi: 10.1001/archpedi.158.6.531.
30. Houghton LA, Szymlek-Gay EA, Gray AR, Ferguson EL,
Deng X, Heath AL. Predictors of vitamin D status and its
association with parathyroid hormone in young New
Zealand children. Am J Clin Nutr 2010; 92: 69-76, doi:
10.3945/ajcn.2009.29055.
31. Abrams SA. Dietary guidelines for calcium and vitamin D: a
new era. Pediatrics 2011; 127: 566-568, doi: 10.1542/peds.
2010-3576.
32. Leino A, Turpeinen U, Koskinen P. Automated measure-
ment of 25-OH vitamin D3 on the Roche Modular E170
analyzer. Clin Chem 2008; 54: 2059-2062, doi: 10.1373/
clinchem.2008.111732.
33. Connell AB, Jenkins N, Black M, Pasco JA, Kotowicz MA,
Schneider HG. Overreporting of vitamin D deficiency with
the Roche Elecsys Vitamin D3 (25-OH) method. Pathology
2011; 43: 368-371, doi: 10.1097/PAT.0b013e328346431c.
34. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin
Proc 2011; 86: 50-60, doi: 10.4065/mcp.2010.0567.
35. Langman CB, Ford KK, Pachman LM, Glorieux F. Vitamin
D metabolism in rats with adjuvant-induced arthritis.
J Bone Miner Res 1990; 5: 905-913, doi: 10.1002/jbmr.
5650050903.
36. Pelajo CF, Lopez-Benitez JM, Kent DM, Price LL, Miller LC,
Dawson-Hughes B. 25-Hydroxyvitamin D levels and juvenile
idiopathic arthritis: Is there an association with disease
activity? Rheumatol Int 2011; doi: 10.1007/s00296-011-
2287-y.
37. Gibson DS, Newell K, Evans AN, Finnegan S, Manning G,
Scaife C, et al. Vitamin D binding protein isoforms as
candidate predictors of disease extension in childhood
arthritis. J Proteomics 2012; 75: 5479-5492, doi: 10.1016/
j.jprot.2012.06.024.
38. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs
JW, et al. Vitamin D levels in women with systemic lupus
erythematosus and fibromyalgia. J Rheumatol 2001; 28:
2535-2539.
39. Celiker R, Bal S, Bakkaloglu A, Ozaydin E, Coskun T, Cetin
A, et al. Factors playing a role in the development of
decreased bone mineral density in juvenile chronic arthritis.
Rheumatol Int 2003; 23: 127-129.
40. Stagi S, Masi L, Capannini S, Cimaz R, Tonini G, Matucci-
Cerinic M, et al. Cross-sectional and longitudinal evaluation
of bone mass in children and young adults with juvenile
idiopathic arthritis: the role of bone mass determinants in a
large cohort of patients. J Rheumatol 2010; 37: 1935-1943,
doi: 10.3899/jrheum.091241.
102 R.V. Munekata et al.
Braz J Med Biol Res 46(1) 2013 www.bjournal.com.br
